What Transformation Has the Tuberculosis Therapeutics Market Undergone?
The tuberculosis therapeutics market has seen considerable growth due to a variety of factors.
• The market dimension for tuberculosis therapeutics has seen remarkable expansion in the last few years. It's projected to surge from $1.88 billion in 2024 to $2.01 billion in 2025, with a compound annual growth rate (CAGR) of 6.58%.
This robust growth witnessed in the prior period can be ascribed to various factors such as growing incidences of tuberculosis, escalating acceptance of tuberculosis therapeutics, improving awareness of tuberculosis (TB), an upward trend in XDR-TB cases, and a rise in the cases of drug-resistant tuberculosis.
What Are The Estimated Market Size And Expected Annual Growth Rates For Globa Tuberculosis Therapeutics Market?
The tuberculosis therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The size of the tuberculosis therapeutics market is projected to experience robust expansion within the next few years, escalating to $2.57 billion in 2029 with a compound annual growth rate (CAGR) of 6.32%.
The predicted growth during this forecast period can be credited to factors such as increased healthcare infrastructure investments, enhanced awareness and education, an increment in research and development investments, a surge in product approvals for various anti-TB agents, amplified funding for research, and a burgeoning elderly population. Key trends expected during this future period encompass breakthroughs in drug development, tailored medicine, combination therapy modalities, digital health innovations, Artificial Intelligence and machine learning's application in the drug discovery process.
What Are The Core Factors Supporting Growth In Tuberculosis Therapeutics Market?
The acceleration in the tuberculosis therapeutics market is predicted to be driven by the surge in co-infection rates of tuberculosis and HIV (TB-HIV). Co-infection rates refer to the proportion of individuals afflicted by both tuberculosis and HIV concurrently. An upswing in TB-HIV co-infections can be attributed to the compromised immunity caused by HIV, which makes people more vulnerable to tuberculosis, coupled with the widespread simultaneous occurrence of both epidemics among populations at high risk. Tuberculosis therapeutics contribute to tackling the rising co-infection rates by offering specific treatments that tackle both the TB infection and the immune suppression caused by HIV. This improves the overall prognosis for patients as well as eases the dual disease burden. For example, as reported by gov.uk in October 2023, England saw 3,805 new HIV diagnoses in 2022, a rise of 22% from the 3,118 cases noted in 2021. Hence, the increasing TB-HIV co-infection rates are fuelling the expansion of the tuberculosis therapeutics market.
What Are The Key Segments Within The Global Tuberculosis Therapeutics Market?
The tuberculosis therapeutics market covered in this report is segmented –
1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB)
2) By Product Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol
3) By Route of Administration: Oral, Parenteral, Other route of administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies
Pre-Book The Tuberculosis Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Tuberculosis Therapeutics Market?
The leading organizations within the tuberculosis therapeutics market are concentrating on the creation of unique solutions such as combined therapy, for upgrading treatment effectiveness, minimizing the therapy period, and tackling drug-resistant tuberculosis strains. Combination therapy involves the implementation of two or more drugs from varied classes to combat a disease. The objective is to elevate treatment effectiveness, curb resistance and enhance patient results. For instance, Johnson & Johnson, a pharmaceutical company based in the USA accomplished a remarkable landmark in tuberculosis treatment in July 2024 by obtaining approval for SIRTURO (bedaquiline) from both the US FDA and the European Commission. This revolutionary drug, the first in more than 40 years specifically crafted to tackle multidrug-resistant tuberculosis (MDR-TB), has a distinct method of action that hampers the ATP synthase enzyme which is crucial for the energy production of TB bacteria. This offers a focused and powerful therapeutic approach. Its involvement in combination therapies boosts the efficiency of MDR-TB regimens comprehensively, shortens treatment duration, and promotes patient adherence.
Who Are the Key Players in the Tuberculosis Therapeutics Market?
Major companies operating in the tuberculosis therapeutics market are include:
• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Sanofi S.A.
• Novartis AG
• GlaxoSmithKline plc
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Macleods Pharmaceuticals Ltd.
• Cipla Limited
• Hikma Pharmaceuticals plc
• Lupin Limited
• Alkem Laboratories Limited
• Emcure Pharmaceuticals Limited
• Otsuka Pharmaceutical Co. Ltd.
• Sequella Inc.
What are the Regional Insights into the Tuberculosis Therapeutics Market?
North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
